JMP Securities slashes price target on Spectrum Pharmaceuticals Inc. [SPPI] – find out why.

Spectrum Pharmaceuticals Inc. [NASDAQ: SPPI] price surged by 7.66 percent to reach at $0.03. The company report on November 25, 2022 that Spectrum Pharmaceuticals Receives Complete Response Letter from U.S. Food and Drug Administration for Poziotinib; Reaffirms Focus on the Commercialization of ROLVEDON™ (eflapegrastim-xnst) injection.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


— Immediately de-prioritizes poziotinib program, accelerates cost reductions, including 75% reduction in R&D related workforce —.

— Spectrum to explore strategic alternatives for the poziotinib program, including partnerships and business development opportunities —.

A sum of 4216132 shares traded at recent session while its average daily volume was at 4.49M shares. Spectrum Pharmaceuticals Inc. shares reached a high of $0.4768 and dropped to a low of $0.38 until finishing in the latest session at $0.46.

The one-year SPPI stock forecast points to a potential upside of 85.16. The average equity rating for SPPI stock is currently 2.20, trading closer to a bullish pattern in the stock market.

Guru’s Opinion on Spectrum Pharmaceuticals Inc. [SPPI]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SPPI shares is $3.10 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SPPI stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

JMP Securities have made an estimate for Spectrum Pharmaceuticals Inc. shares, keeping their opinion on the stock as Mkt Outperform, with their previous recommendation back on September 17, 2020. The new note on the price target was released on December 26, 2019, representing the official price target for Spectrum Pharmaceuticals Inc. stock. Previously, the target price had yet another drop from $17 to $4, while Cantor Fitzgerald kept a Neutral rating on SPPI stock.

The Average True Range (ATR) for Spectrum Pharmaceuticals Inc. is set at 0.04 The Price to Book ratio for the last quarter was 2.43, with the Price to Cash per share for the same quarter was set at 0.50.

SPPI Stock Performance Analysis:

Spectrum Pharmaceuticals Inc. [SPPI] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 2.78. With this latest performance, SPPI shares gained by 6.81% in over the last four-week period, additionally sinking by -34.83% over the last 6 months – not to mention a drop of -73.72% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SPPI stock in for the last two-week period is set at 49.62, with the RSI for the last a single of trading hit 54.43, and the three-weeks RSI is set at 45.81 for Spectrum Pharmaceuticals Inc. [SPPI]. The present Moving Average for the last 50 days of trading for this stock 0.4806, while it was recorded at 0.4330 for the last single week of trading, and 0.8245 for the last 200 days.

Insight into Spectrum Pharmaceuticals Inc. Fundamentals:

Return on Equity for this stock declined to -174.30, with Return on Assets sitting at -102.77.

Spectrum Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.10 and a Current Ratio set at 2.30.

Spectrum Pharmaceuticals Inc. [SPPI] Insider Position Details

There are presently around $24 million, or 26.30% of SPPI stock, in the hands of institutional investors. The top three institutional holders of SPPI stocks are: ARMISTICE CAPITAL, LLC with ownership of 16,676,000, which is approximately -2.48% of the company’s market cap and around 1.60% of the total institutional ownership; VANGUARD GROUP INC, holding 8,667,120 shares of the stock with an approximate value of $4.01 million in SPPI stocks shares; and BLACKROCK INC., currently with $3.34 million in SPPI stock with ownership of nearly -8.365% of the company’s market capitalization.

Positions in Spectrum Pharmaceuticals Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 36 institutional holders increased their position in Spectrum Pharmaceuticals Inc. [NASDAQ:SPPI] by around 4,397,355 shares. Additionally, 49 investors decreased positions by around 11,031,277 shares, while 17 investors held positions by with 37,277,112 shares. The mentioned changes placed institutional holdings at 52,705,744 shares, according to the latest SEC report filing. SPPI stock had 18 new institutional investments in for a total of 2,038,201 shares, while 23 institutional investors sold positions of 2,057,232 shares during the same period.


Please enter your comment!
Please enter your name here